Updated on 28 April 2015
R-Tech Ueno Ltd, headquartered in Tokyo, has acquired the right to develop and commercialize DE-105 from Santen Pharmaceutical Co. Ltd.
DE-105 is a treatment targeting at persistent corneal epithelial defects that Santen has been developing. By acquisition of this right, R-Tech Ueno will undertake the development and commercialization of the product.
In addition to this agreement, R-Tech Ueno has also signed an agreement with the inventor of DE-105, Professor Emeritus Teruo Nishida as medical advisor of R-Tech
DE-105 is an ophthalmic solution of neurotrophic factor peptide, discovered and developed from academia.
It has been developed as a treatment for severe persistent corneal epithelial defects caused by corneal sensory nerve disorder (currently at the stage of Phase I clinical trial in the United States and Phase II clinical trial in Japan).
Damage to corneal sensory nerves causes various corneal and conjunctival epithelial disorders (persistent corneal epithelial defects, post-LASIK corneal epithelial defects, severe dry eye, disorder associated with decreased corneal sensitivity caused by long-term contact lens wear, etc.); however, the company claims that treatment utilizing existing ophthalmic solutions has not been satisfying.